Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US7932260B2 · kind B2 · utility
167Cited by
41References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2005 |
| Grant date | Apr 26, 2011 |
| Priority date | — |
| Expiry date | Aug 5, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3Kδ activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.